GGrantIndex
← Search

ACTG 398 PHASE II TRIAL OF AMPRENAVIR ABACAVIR, EFAVIRENZ &ADEFOVIR

$47,556M01FY2000RRNIH

Mount Sinai School Of Medicine Of Cuny, New York NY

Investigators

Linked publications & trials

Abstract

This Phase II trial will compare the proportion of subjects achieving a plasma HIV-1RNA concentration below 200 copies/ml across the study arms at 24 weeks as assessed by the Roche Ultra Sensitive assay. It will also compare the time to quantifiable viremia (defined as a confirmed plasma HIV-1RNA concentration > 200 copies/ml) across the study arms.

View original record on NIH RePORTER →